Abstract
A novel, one-pot, multicomponent synthesis of triazolothiadiazine derivatives have been achieved starting from 4-amino-4H-1,2,4-triazole-3,5-dithiol and variously substituted phenacyl bromides. The synthesis involves the simultaneous formation of two C–S and one C = N bond. The newly synthesized compounds were characterized by IR, 1H NMR, 13C NMR, and mass spectral data. The advantages of this method are good yields, high purity, shorter reaction times and simple purification technique. The synthesized target compounds were screened for their in vitro anticancer activity at concentration 10−5 M against 60 cancer cell lines. Among all the compounds, 1-(4-Fluorophenyl)-2-((6-(4-fluorophenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazin-3-yl) thio)ethanone (4d), 1-(4-Bromophenyl)-2-((6-(4-bromophenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazin-3-yl)thio) ethanone (4f), and 2-((6-(4-Chlorophenyl)-7H-[1,2,4] triazolo[3,4-b][1,3,4]thiadiazin-3-yl)thio)-1-(4-fluorophenyl)ethanone (4l) exhibited significant activity in terms of growth percent against renal cancer OU-31 cell line with 47.42%, 46.76%, 48.14%. The compound 2-((6-(4-Chlorophenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazin-3-yl)thio)-1-(4-fluorophenyl) ethanone (4l) also exhibited significant activity on leukemia MOLT-4 cell line with 49.82%.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Phosphorus, Sulfur, and Silicon and the Related Elements
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
